SVCM
Saturn V Capital Management Portfolio holdings
AUM
$247M
This Quarter Return
+11.61%
1 Year Return
+2.68%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$249M
AUM Growth
+$249M
(-4.5%)
Cap. Flow
-$29.7M
Cap. Flow
% of AUM
-11.9%
Top 10 Holdings %
Top 10 Hldgs %
71.1%
Holding
28
New
5
Increased
5
Reduced
10
Closed
7
Top Buys
| 1 |
Vaxcyte
PCVX
|
$12.6M |
| 2 |
Disc Medicine
IRON
|
$11.8M |
| 3 |
ABVX
Abivax
ABVX
|
$8.91M |
| 4 |
Ironwood Pharmaceuticals
IRWD
|
$8.23M |
| 5 |
Amicus Therapeutics
FOLD
|
$8.23M |
Top Sells
| 1 |
CBAY
Cymabay Therapeutics
CBAY
|
$17.7M |
| 2 |
Amylyx Pharmaceuticals
AMLX
|
$16.2M |
| 3 |
Cytokinetics
CYTK
|
$12.9M |
| 4 |
Biogen
BIIB
|
$8.4M |
| 5 |
Astria Therapeutics
ATXS
|
$7.61M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Crinetics Pharmaceuticals
CRNX
$2.92B
| $30.9M | 12.39% | 660,143 -126,989 | -16% | -$5.94M |
|
2
argenx
ARGX
$43.6B
| $25.8M | 10.35% | 65,597 +14,422 | +28% | +$5.68M |
|
|
3
Cytokinetics
CYTK
$4.23B
| $18.5M | 7.41% | 263,701 -184,443 | -41% | -$12.9M |
|
4
KalVista Pharmaceuticals
KALV
$678M
| $17.1M | 6.86% | 1,441,952 -365,611 | -20% | -$4.34M |
|
5
Merus
MRUS
$4.98B
| $17M | 6.8% | 376,629 -12,704 | -3% | -$572K |
|
|
6
Disc Medicine
IRON
$2.07B
| $15.9M | 6.36% | 254,803 +190,019 | +293% | +$11.8M |
|
7
Ascendis Pharma
ASND
$11.8B
| $15.6M | 6.27% | 103,428 -28,331 | -22% | -$4.28M |
|
8
AnaptysBio
ANAB
$569M
| $13.2M | 5.29% | 586,031 -78,245 | -12% | -$1.76M |
|
|
9
Vaxcyte
PCVX
$4B
| $12.6M | 5.07% | +185,175 | New | +$12.6M |
|
10
Cogent Biosciences
COGT
$1.69B
| $10.7M | 4.3% | 1,595,021 +838,340 | +111% | +$5.63M |
|
|
11
Amicus Therapeutics
FOLD
$2.34B
| $10.6M | 4.24% | 898,381 +698,408 | +349% | +$8.23M |
|
12
BioMarin Pharmaceuticals
BMRN
$11.2B
| $10.4M | 4.17% | 119,188 | – | – |
|
13
Syndax Pharmaceuticals
SNDX
$1.41B
| $9.47M | 3.8% | 397,997 -120,802 | -23% | -$2.88M |
|
|
ABVX
14
Abivax
ABVX
$6.12B
| $8.91M | 3.57% | +622,970 | New | +$8.91M |
|
|
15
Ironwood Pharmaceuticals
IRWD
$214M
| $8.23M | 3.3% | +944,912 | New | +$8.23M |
|
16
Phathom Pharmaceuticals
PHAT
$864M
| $5.32M | 2.13% | 500,987 +340,912 | +213% | +$3.62M |
|
17
iTeos Therapeutics
ITOS
| $5.28M | 2.12% | 387,095 -441,137 | -53% | -$6.02M |
|
18
Apellis Pharmaceuticals
APLS
$3.48B
| $4.2M | 1.68% | 71,463 -71,464 | -50% | -$4.2M |
|
19
Geron
GERN
$893M
| $3.71M | 1.49% | +1,123,995 | New | +$3.71M |
|
|
MORF
20
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $3.01M | 1.21% | 85,632 -126,711 | -60% | -$4.46M |
|
21
Cabaletta Bio
CABA
$133M
| $2.95M | 1.18% | +173,173 | New | +$2.95M |
|
22
Alnylam Pharmaceuticals
ALNY
$58.5B
| – | – | -10,327 | Closed | -$1.98M |
|
|
23
Amylyx Pharmaceuticals
AMLX
$836M
| – | – | -1,099,268 | Closed | -$16.2M |
|
|
24
Astria Therapeutics
ATXS
$349M
| – | – | -990,663 | Closed | -$7.61M |
|
|
25
Biogen
BIIB
$19.4B
| – | – | -32,469 | Closed | -$8.4M |
|